Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this cre

Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier

Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the compan

Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and lowers

Wall Street analysts changed outlook on top names, including Alphine Income Property Trust, AAR Corp

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday

Read Also: Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 poi

US stocks higher, Nasdaq up 1%. Dow up 0.60%, Nasdaq up 1.34%, S&P 500 up 0.82%. Communication s

Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechn

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommu

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) with a Buy and

Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and raises

Evommune (NYSE:EVMN) reported quarterly losses of $(0.64) per share which beat the analyst consensus

 Up to 4,494,279 Shares of Common StockThis prospectus relates to the resale from time to time of up

RBC Capital analyst Brian Abrahams reiterates Evommune (NYSE:EVMN) with a Outperform and maintain

Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright &

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Evommune (NYSE:EVMN) with a Buy and

Clear Street analyst Kaveri Pohlman initiates coverage on Evommune (NYSE:EVMN) with a Buy rating

Evommune (NYSE:EVMN) reported quarterly losses of $(1.43) per share which missed the analyst consens

The Benzinga Stock Whisper Index highlights five stocks seeing strong interest from readers during t

Evommune stock slips after a 70% rally on strong Phase 2 eczema data. Analysts raises success odds a

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Evommune (NYSE:EVMN) with a Buy and

Evommune shares jumped after its mid-stage trial showed strong skin improvement and good safety for

- Trial met primary efficacy endpoint at week 12- EVO301 produced rapid, statistically significant E

Oppenheimer analyst Andreas Argyrides initiates coverage on Evommune (NYSE:EVMN) with a Outperfor

Raymond James analyst Martin Auster initiates coverage on Evommune (NYSE:EVMN) with a Strong Buy

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Evommune (NYSE:EVMN) wit

Evommune gains an Outperform rating as William Blair cites strong EVO756 trial data and blockbuster

Morgan Stanley analyst Judah Frommer initiates coverage on Evommune (NYSE:EVMN) with a Overweight

Leerink Partners analyst Thomas Smith initiates coverage on Evommune (NYSE:EVMN) with a Outperfor

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Evommune (NYSE:EVMN) with a